TherapeuticsMD, Inc. (NASDAQ:TXMD) was the target of a significant growth in short interest in the month of October. As of October 13th, there was short interest totalling 41,131,584 shares, a growth of Infinity from the September 29th total of 0 shares. Currently, 23.7% of the company’s shares are sold short. Based on an average trading volume of 3,688,148 shares, the days-to-cover ratio is presently 11.2 days.
In other news, Director Tommy G. Thompson purchased 5,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were acquired at an average price of $5.99 per share, with a total value of $29,950.00. Following the completion of the purchase, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 23.92% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. lifted its holdings in TherapeuticsMD by 26.6% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock worth $756,000 after buying an additional 30,030 shares during the period. Cetera Investment Advisers acquired a new position in TherapeuticsMD during the 2nd quarter worth about $214,000. The Manufacturers Life Insurance Company lifted its holdings in TherapeuticsMD by 3.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 123,580 shares of the company’s stock worth $651,000 after buying an additional 4,058 shares during the period. State Street Corp lifted its holdings in TherapeuticsMD by 14.9% during the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after buying an additional 583,094 shares during the period. Finally, Stifel Financial Corp lifted its holdings in TherapeuticsMD by 377.9% during the 2nd quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after buying an additional 1,622,668 shares during the period. 71.55% of the stock is currently owned by hedge funds and other institutional investors.
TXMD has been the topic of several research reports. Oppenheimer Holdings, Inc. set a $10.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research note on Thursday, August 17th. Deutsche Bank AG initiated coverage on TherapeuticsMD in a research note on Friday, July 21st. They set a “buy” rating and a $10.00 price target on the stock. Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Friday, August 4th. Jefferies Group LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of TherapeuticsMD in a research note on Friday, August 11th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price target on shares of TherapeuticsMD in a research note on Monday, August 21st. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $14.88.
TherapeuticsMD (NASDAQ TXMD) opened at 4.80 on Monday. The firm’s market cap is $979.33 million. The firm has a 50-day moving average price of $4.87 and a 200 day moving average price of $4.87. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The firm had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative return on equity of 74.25% and a negative net margin of 485.71%. The business’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.11) EPS. Equities analysts predict that TherapeuticsMD will post ($0.44) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Short Interest in TherapeuticsMD, Inc. (TXMD) Grows By Infinity” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/10/30/short-interest-in-therapeuticsmd-inc-txmd-grows-by-infinity.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
What are top analysts saying about TherapeuticsMD Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TherapeuticsMD Inc. and related companies.